MA-NUMARES
15.12.2021 14:17:09 CET | Business Wire | Press release
Leading NMR diagnostics company numares AG appoints Dr. Gregory Heath as new member of the Supervisory Board. Dr. Heath has a long career in the diagnostics and life sciences industry, including long-term experience in the development and launching of in vitro diagnostics (IVDs). He will assist numares in the commercialization of multi-marker-based diagnostic tests running on the company’s proprietary, AI-driven IVD platform, the AXINON® System , for which the company applied for two 510(k) clearances this year.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211215005040/en/
“We are delighted to welcome Greg to the board,” said Dr. Volker Pfahlert, Chief Executive Officer of numares . “As we continue our focus on expansion in the United States, his depth of knowledge and substantial experience in the US diagnostics industry will help drive our diagnostic strategy and be invaluable to numares as it launches IVD products."
With his appointment, Dr. Heath joins the numares Supervisory Board as the second, independent US expert after Ms. Kathy Bates of Mayo Clinic Laboratories, who has been supporting the Supervisory Board as first US advisor since her election in 2019.
He brings with him more than 30 years of diagnostics experience. As a former General Manager of Diagnostics at Illumina Inc., Dr. Heath was responsible for building and managing the molecular Diagnostics Business Unit, as well as for the establishment of a CLIA lab and acquisition of service labs. Prior to this, he was SVP, Molecular Business at Roche Diagnostics, and held numerous roles in strategy, marketing, and business development during his career. He currently serves on the Scientific Advisory Board of Everlywell and is a strategic and scientific advisor to the diagnostics and life sciences industry.
Winton Gibbons, President of numares GROUP in the US and co-CEO of numares AG adds "Greg is a great addition to our Supervisory Board. His extensive experience in the diagnostics industry will help numares to commercialize its pipeline of new tests in the US. These include AXINON® GFR(NMR) , a novel multi-marker kidney function test, recently submitted for FDA clearance."
Earlier this year, numares also announced its FDA 510(k) application for the AXINON® LDL-P test on the AXINON® System , an IVD platform based on Nuclear Magnetic Spectroscopy (NMR), combined with the company’s proprietary Magnetic Group Signaling (MGS® ). MGS® enables simultaneous, highly standardized analysis of metabolites in human samples like blood and urine. The platform is used to develop and deploy novel diagnostic tests in clinical laboratories, applying the “numares model, ” that identifies a set of metabolites, so-called "biomarker constellations,” via machine learning algorithms. This provides diagnostics solutions for the prevention and treatment of disease, including conditions in the kidney, heart, and liver, as well as cancer.
At the numares shareholders’ meeting in December 2021, Dr. Heath was elected as member of the supervisory board effective January 1st, 2022.
You will find more information at https://www.numares.com/ and on our social media channels: LinkedIn , Facebook , YouTube and Twitter .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211215005040/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Novotech Strengthens Presence in Japan with Opening of Tokyo Office24.8.2026 01:01:00 CEST | Press release
Novotech, a leading global biotech CRO and full-service clinical research organization, has strengthened its established presence in Japan with the opening of a new office in Tokyo. The investment builds on Novotech’s existing operations and clinical trial activity in Japan and further enhances its ability to support Japanese biopharma companies as they advance programs regionally and across key international markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823592174/en/ Takeshi Mori, Novotech Country Head, Japan The Tokyo office will serve as a strategic hub for Novotech’s growing operations in Japan, providing enhanced local expertise and strengthening collaboration with clients, partners, research institutions, and innovation ecosystems across the region. Novotech is currently supporting ongoing studies in Japan and provides sponsors with integrated support across early-phase clinical development in Australia, F
FDA Authorizes ZYN ULTRA Nicotine Pouches Following Scientific Review21.8.2026 21:11:00 CEST | Press release
Authorizations add selection of ZYN ULTRA products to PMI U.S.’s growing portfolio of better alternatives for legal-age adults who smoke or use traditional oral tobacco products Philip Morris International Inc. (NYSE: PM) today announces that the U.S. Food and Drug Administration (FDA) issued Marketing Granted Orders to PMI’s U.S. affiliate, Swedish Match USA, Inc., authorizing the marketing of 11 ZYN ULTRA moist oral nicotine pouch products, including all 9mg variants and one 11mg variant. Additional 11mg variants remain under scientific review. Today’s action further enhances PMI’s leadership role in the smoke-free category. “We are delighted with the FDA’s decision to authorize a range of ZYN ULTRA products, which will build on ZYN’s position as America’s leading smoke-free product brand,” said Stacey Kennedy, PMI U.S. CEO. “We look forward to expanding our portfolio of better choices for the 45 million Americans who consume nicotine products.” ZYN ULTRA positions the brand to furth
58% of Consumers Say They Don't Care Whether a Product is a National Brand or Private Label. They Just Buy What They Need21.8.2026 12:00:00 CEST | Press release
New NIQ & World Data Lab report reveals how consumer polarization is redefining value, accelerating private label adoption, and reshaping competition on the shelf As fast-moving consumer goods (FMCG) prices rose 26% globally between 2021 and 2025, consumers have become more deliberate about where they save and where they spend. NielsenIQ (NYSE: NIQ) has released new findings showing that private label is no longer viewed simply as a lower-cost substitute, but as a credible competitor across value, mainstream, and premium segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260819950224/en/ Private label is no longer just a value play. The findings, published in NIQ’s latest report, A Tale of Two Consumers: The Polarized Mindsets Reshaping Global Consumption, created in collaboration with World Data Lab, show how consumer polarization is redefining value and reshaping competition on the shelf. The report also draws on ins
Tanium Reappoints Co-Founder Orion Hindawi as CEO to Drive Next Chapter of Growth20.8.2026 21:10:00 CEST | Press release
Company to focus on deepening its Autonomous IT capabilities, further expanding AI offerings across its portfolio, and strengthening customer and partner engagement Tanium, a leader in Autonomous IT, today announced that Co-Founder and Executive Chairman Orion Hindawi has been appointed Chief Executive Officer, effective immediately. Dan Streetman is stepping down as CEO and as a member of the Board after leading Tanium for the last three years, during which time Tanium scaled its go-to-market operations and secured strong industry analyst recognition for innovation within the Tanium platform. Streetman will continue to advise Tanium as part of the transition and co-founder David Hindawi will return to the role of Chairman of the Board. With this foundation in place, this transition positions Tanium to deepen its Autonomous IT capabilities and further expand AI offerings across its portfolio and strengthen customer and partner engagement. The Hindawis co-founded Tanium in 2007 to build
PCI Energy Solutions to Join Mitsubishi Electric, Reinforcing Long-Term Commitment to Customers, Employees, and the Energy Industry20.8.2026 19:46:00 CEST | Press release
Mitsubishi Electric to retain PCI’s core management team and support continuity of operations, customer service, and product innovation PCI Energy Solutions ("PCI"), a leading U.S.-based provider of enterprise software for energy management and optimization, announced today that it has entered into a definitive agreement to be acquired by Mitsubishi Electric Corporation. The agreement was executed on August 20, 2026 (Japan Standard Time). The Transaction represents a strong endorsement of PCI's business, technology, employees, customer relationships and position in the energy industry. Mitsubishi Electric intends to retain PCI's core management team following completion of the Transaction, enabling PCI to preserve leadership continuity, industry expertise and its customer-focused operating model while benefiting from Mitsubishi Electric's global scale, complementary capabilities and long-term investment capacity. The agreement has been signed, but the Transaction has not yet closed. PC
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom